SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of Eleven Biotherapeutics, Inc. -- EBIO

Levi & Korsinsky announces it has commenced an investigation of Eleven Biotherapeutics, Inc. (NASDAQGM: EBIO) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On January 15, 2016, Eleven Biotherapeutics said its lead eye drug, codenamed EBI-005 and now called isunakinra, failed in a late-stage trial to treat patients with severe allergic conjunctivitis. Specifically, the Company disclosed that there were no statistically significant differences between the isunakinra treated group and the vehicle control group on the primary endpoint, reducing ocular itching, or any of the secondary endpoints. Shares of Eleven Biotherapeutics were down 72.22% on intraday trading on January 19, 2016. To obtain additional information, go to:

http://zlk.9nl.com/eleven-biotherapeutics-ebio

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160119006530/en/